Treatment of Metaplastic Breast Cancer in the U.S.: Asian Patient Receives Latest Treatment Plan via Remote Video Consultation with Leading U.S. Experts
- medebound
- Jan 13, 2025
- 12 min read
Updated: 1 day ago
Author: Medical Editor Jasmine
What is Metaplastic Breast Cancer, and how common is it?
Metaplastic breast cancer is a rare, highly aggressive form of breast cancer, accounting for less than 1% of all breast cancers. The incidence generally ranges from 0.2% to 1%. It is often detected as a rapidly enlarging mass in the breast. Although it appears similar to invasive ductal carcinoma on imaging tests, the tumor size of metaplastic breast cancer is often larger at diagnosis.
WHO Breast Tumor Classification classifies metaplastic breast cancer as mixed metaplastic carcinoma, low-grade adenosquamous carcinoma, fibromatosis-like carcinoma, squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with stromal differentiation. Most metaplastic breast cancers are triple-negative breast cancers (i.e., do not express estrogen receptor, progesterone receptor, or HER2 protein), which limits the effectiveness of traditional endocrine and targeted therapies. Due to its unique biological behavior, metaplastic breast cancer generally has a poor prognosis and requires individualized treatment plans.
How is Metaplastic Breast Cancer treated?
Metaplastic breast cancer is characterized by its tendency to spread to areas outside the breast. Due to the lack of clear treatment guidelines, the approach is generally more aggressive.
Treatment strategies depend on the cancer's stage and may include chemotherapy (to shrink the tumor, though standard chemotherapy regimens may have limited efficacy and may be combined with immunotherapy), surgery (tumor removal, with bilateral mastectomy as an option), radiation therapy (to shrink the tumor, kill cancer cells, and relieve pain), and newer therapies (such as targeted therapy, immune modulators, and antibody-drug conjugates, which may serve as potential alternatives to standard chemotherapy).
Since metaplastic breast cancer accounts for less than 1% of all breast cancer diagnoses and clinical trials are limited, its treatment typically follows similar principles to other breast cancers of the same stage and characteristics. Additionally, to reduce the risk of development, it is recommended to undergo regular mammography screenings as advised by a doctor.
Can Metaplastic Breast Cancer be cured?
Metaplastic breast cancer is a rare and aggressive type of breast cancer that is harder to treat than most other forms. It often grows and spreads quickly, and is more likely to be found at a later stage. While some people do achieve long-term remission, for many, the goal of treatment is to control the disease rather than cure it completely. Large studies show that about half of patients with metaplastic breast cancer are alive five years after diagnosis (around 50–56%) compared to roughly three-quarters of patients with triple-negative invasive ductal carcinoma (73.3%) . Among the different subtypes, spindle-cell metaplastic breast cancer tends to have the lowest survival rates around 40% in some reports
Pain Points for International Patients with Metaplastic Breast Cancer
For families facing a serious diagnosis, accessing advanced therapies in the U.S. often feels out of reach.
Challenge 1: Difficulty in Choosing Treatment Options
Patients may lack understanding of various treatment options (such as medications or surgery), making it challenging to make informed decisions.
Challenge 2: High Medical Costs
Long-term treatment for breast cancer can lead to significant financial strain for patients, not including the expenses of long-distance travel, accommodation, and living costs. Moreover, 95% of international patients lack insurance coverage for these expenses.
Challenge 3: Language and Cultural Barriers
International patients may face challenges related to language communication and cultural differences when seeking medical care across countries, which can affect the effectiveness of treatment.
Challenge 4: The Need for Long-Term Stay in the U.S. or Frequent Travel Between Countries
Treatment for metaplastic breast cancer is a long-term process, and temporary relief does not equal long-term remission. For some patients, traveling to the U.S. may mean a prolonged stay, or the need for frequent back-and-forth travel between countries.
So, is there a way to help reduce the burden on patients?
Yes, indeed there is.
Case of an Asian Metaplastic Breast Cancer Patient Receiving Remote Video Consultation with U.S. Experts
The Patient
"Ms. Yang" (pseudonym), 56, presented with one of the rarest and most treatment-resistant subtypes of breast cancer: metaplastic breast cancer, accounting for just 1–2% of all breast cancer diagnoses. Its atypical cell morphology, lack of uniform treatment standards, and poor prognosis make it among the most clinically challenging breast cancers to manage.
Her history was already complex — a right breast invasive ductal carcinoma in December 2022, treated with chemotherapy, surgery, and radiotherapy, followed by a new left breast diagnosis in April 2024: invasive ductal carcinoma and triple-negative breast cancer (TNBC). Despite multiple chemotherapy attempts, the tumor continued to progress, ultimately requiring a left mastectomy in September 2024. Postoperative pathology confirmed lymph node metastasis — an occurrence seen in only 10% of metaplastic breast cancer cases, signaling an aggressive disease course.
The Clinical Need
With both chemotherapy and immunotherapy proving ineffective, the complexity of this rare subtype had exceeded locally available clinical experience. Ms. Yang's treating physician sought an expert clinical exchange with a U.S.-based rare breast cancer specialist to inform the next stage of management.
Medebound HEALTH facilitated this cross-border collaboration, connecting the local treating team with "Dr. Najmi" (pseudonym), a breast cancer specialist with a professional appointment at Memorial Sloan Kettering Cancer Center (MSKCC), New York, directing the institution's Rare Breast Cancer Program and co-leading its Triple-Negative Breast Cancer Clinical Research initiative. MSKCC is consistently ranked among the top cancer centers in the United States and is a designated NCI Comprehensive Cancer Center.
The Collaborative Consultation
Dr. Najmi conducted a thorough review of Ms. Yang's full medical records, pathology reports, and imaging ahead of the session. In the subsequent video exchange, Dr. Najmi and the local treating team engaged in a detailed clinical discussion — confirming the diagnosis of metaplastic breast cancer, sarcomatoid cell subtype — and worked through treatment options, drug selection, and genetic counseling considerations together.
The Clinical Direction Established
Drawing on his experience with rare breast cancer subtypes, Dr. Najmi shared the following clinical perspectives with the local team:
Emerging treatment pathway: Given resistance to both chemotherapy and immunotherapy, the U.S. expert advised exploring a novel antibody-drug conjugate (ADC) regimen as a promising avenue beyond conventional treatment lines
Clinical trial access: Dr. Najmi identified enrollment in an ADC-related clinical trial as a concrete pathway to cutting-edge therapy under monitored conditions
Radiotherapy reassessment: The local team was advised to engage a radiation oncologist to evaluate the role of adjuvant radiotherapy
Genetic counseling guidance: BRCA1 variant of uncertain significance noted — family genetic testing encouraged but not mandatory; clinical significance to be monitored longitudinally
Surveillance framework: Given high recurrence risk, Dr. Najmi outlined a rigorous monitoring protocol — PET scans every 3 months in year one, every 4 months in year two, every 6 months in year three, supplemented by circulating tumor DNA testing from year two onward
Key clinical caution: Any suspected lesion requires biopsy confirmation; immunotherapy-related pseudo-progression must be carefully distinguished from true disease progression
The Outcome
The collaborative consultation equipped the local treating team with an evidence-based framework and direct access to the latest U.S. clinical data on a disease subtype where evidence globally remains scarce — at a point where standard options had been exhausted.
"Learning about the new antibody-drug conjugate options and clinical trials gave me new hope and direction. It strengthened my confidence in fighting this disease." — Ms. Yang, as relayed through her treating physician
Ms. Yang's family, moved by the outcome, proactively referred three other patients to the same consultation service — a testament to the impact of the clinical direction established.
Key Takeaway
Metaplastic breast cancer demands expertise that few institutions worldwide possess. When standard treatment fails and options narrow, a structured international expert consultation — connecting local treating physicians with U.S. specialists in rare cancer subtypes — can unlock clinical trial pathways, emerging drug options, and evidence-based surveillance strategies that would otherwise remain out of reach.
Advantages of Treating Metaplastic Breast Cancer in the U.S.
The U.S. offers several advantages in the treatment of metaplastic breast cancer compared to other countries or regions, primarily in the following aspects:
1.Advanced Medical Technology and Innovative Therapies
The U.S. is at the forefront of precision medicine and personalized treatment for breast cancer. For metaplastic breast cancer, U.S. clinicians may employ more advanced surgical techniques, radiation methods, and innovative drug therapies such as targeted therapy and immunotherapy. These treatments may significantly improve patient survival rates and quality of life.
For example, targeted drugs or immunotherapies developed for specific gene mutations or abnormal signaling pathways may be utilized in the U.S., therapies that might still be in the research phase or less commonly used in other regions.
2.Rich Clinical Experience and Multidisciplinary Comprehensive Treatment
The U.S. is home to many specialized breast cancer treatment centers and medical teams with extensive clinical experience.
Given the complexity and rarity of metaplastic breast cancer, U.S. hospitals typically adopt a multidisciplinary approach, involving experts from surgery, oncology, radiation therapy, pathology, and imaging, who collaborate to formulate the most effective treatment plan, ensuring the best possible outcome for patients.
3.Strict Medical Quality Regulation and Assurance
The U.S. has a well-established medical quality regulatory system, with strict guidelines and oversight concerning hospital and physician qualifications, medical equipment certifications, and drug approvals.
This helps ensure that patients with metaplastic breast cancer receive high-quality medical services and safe drug treatments throughout their treatment journey.
4.Higher Survival Rates
According to statistics, the five-year survival rate for breast cancer patients in the U.S. is relatively high, likely due to advanced medical technology, extensive clinical experience, and a robust regulatory system.
Although metaplastic breast cancer generally has a poorer prognosis, the U.S. may offer a higher success rate and better patient outcomes in treating this rare subtype.
5.Continuous Research Investment and Innovation
The U.S. makes substantial investments in medical research, which helps drive the continuous innovation and development of breast cancer treatments.
For metaplastic breast cancer and other complex subtypes, U.S. scientists and doctors are likely to conduct more clinical studies and trials to explore more effective treatment methods.
Latest Advances in Treating Metaplastic Breast Cancer in the U.S.
As mentioned earlier, metaplastic breast cancer is typically triple-negative breast cancer (TNBC) and does not respond to hormone therapies used for ER+, PR+, or HER2+ cancers. Due to its often chemotherapy-resistant nature, there is currently no specific treatment standard. Thus, patients diagnosed with metaplastic breast cancer are generally treated with chemotherapy regimens used for triple-negative breast cancer.
Antibody-Drug Conjugates: Sacituzumab Govitecan (Trodelvy)
Sacituzumab Govitecan (Trodelvy) is a Trop-2 targeted antibody-drug conjugate used for metastatic triple-negative breast cancer (mTNBC). In the global Phase III ASCENT trial, Trodelvy significantly improved progression-free survival, overall survival, and objective response rates. The U.S. FDA has approved it for the treatment of adults with locally advanced or mTNBC who have received at least two prior therapies.
Antibody-Drug Conjugates: Trastuzumab Deruxtecan (T-DXd)
Results from the Phase 3 DESTINY-Breast06 clinical trial presented at the 2024 American Society of Clinical Oncology (ASCO) meeting showed that, compared to chemotherapy, trastuzumab deruxtecan significantly extended progression-free survival by approximately 5 months in patients with metastatic HR-positive, HER2-low, and HER2 ultra-low breast cancer. T-DXd is poised to redefine the treatment of metastatic breast cancer.
Pembrolizumab (KEYTRUDA)
In the U.S., KEYTRUDA can be used for high-risk early-stage triple-negative breast cancer (TNBC) patients in combination with chemotherapy as neoadjuvant therapy, and as a single agent for adjuvant therapy following surgery.
KEYTRUDA in combination with chemotherapy is also FDA-approved for the treatment of locally recurrent, unresectable, or metastatic TNBC patients whose tumors express PD-L1 (CPS ≥10).
Leading Hospitals and Experts in Treating Metaplastic Breast Cancer in the U.S.
MD Anderson Cancer Center
Location: Houston, Texas
Advantages: MD Anderson's breast cancer specialists are experts in diagnosing and staging rare cancers and developing new treatment methods. Their research findings are applied to about 60% of the cancer drugs approved by the FDA in 2023. In the 2024-2025 U.S. News & World Report "Best Hospitals" rankings, MD Anderson Cancer Center was recognized as the top cancer treatment hospital in the U.S. Additionally, MD Anderson provides personalized care and multidisciplinary treatment at five locations in the Houston area.
Mayo Clinic
Location: Rochester, Minnesota
Advantages: Renowned for its comprehensive healthcare, Mayo Clinic's oncology department is known for its outstanding medical team and innovative treatment methods. The clinic offers efficient diagnostic and therapeutic services for breast cancer patients, from genetic testing to comprehensive treatment, particularly excelling in treating high-risk or recurrent breast cancer patients.
Memorial Sloan Kettering Cancer Center (MSKCC)
Location: New York City
Advantages: One of the oldest and largest cancer centers in the world, MSKCC is ranked as the second-best cancer hospital in the U.S. MSKCC has a specialized program for rare breast cancers, focusing on providing the latest antibody-drug conjugates and clinical trials, offering patients cutting-edge treatment options. The hospital has over 120 laboratories dedicated to various types of cancer research, providing technical and expert support for researchers.
How Medebound HEALTH Supports You:
1. Initial Consultation: Connect with us to discover your needs. Our dedicated care team will concisely outline all treatment options, ensuring you understand each choice without feeling overwhelmed or stressed.
2. Doctor Consultation: We'll arrange a remote video consultation with an expert from a prestigious U.S. hospital. Language barriers are no issue, as we provide professional translation services to facilitate clear and comfortable communication between you and the doctor about your condition and recovery goals.
3. Tailored Treatment Plan: Following the doctor's consultation, we'll help you devise a personalized treatment plan. We'll clearly explain which treatments may be advantageous for you, the duration of treatment, associated costs, and expected outcomes.
4. Travel Facilitation: If traveling to the U.S. for treatment is necessary, we'll streamline the process for you. We'll handle visa applications, flight bookings, accommodations near the hospital, airport transfers, and all travel arrangements for your family.
5.Hospital Arrival Support: Upon arrival at the U.S. hospital, our team will be there to guide you through every step. We'll assist with doctor communication, explain treatment plans, support your family, and leverage our years of partnership with U.S. hospitals to secure the maximum discount for you, which can sometimes reach 15%-50%—far surpassing the discounts patients can typically negotiate on their own.
6. Ongoing Recovery Support: Even after returning home, our care continues. We'll support your rehabilitation efforts, monitor your recovery progress, arrange follow-up doctor consultations as needed, and be with you every step of the way until you achieve your recovery goals.
FAQ on Metaplastic Breast Cancer & U.S. Treatment Options
1. What is metaplastic breast cancer?
Metaplastic breast cancer is a rare, aggressive type of breast cancer, accounting for less than 1% of all breast cancers, often triple-negative, and usually diagnosed at a later stage.
2. How common is it?
It affects about 0.2%–1% of all breast cancer patients.
3. How is it treated?
Treatment may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, or antibody-drug conjugates, often in a combined, aggressive approach.
4. Can it be cured?
Long-term remission is possible for some patients, but cure rates are low due to its aggressive nature. Five-year survival is about 50–56%, lower for certain subtypes.
5. Why is it harder to treat than other breast cancers?
It often resists standard chemotherapy, lacks hormone receptors, and is usually triple-negative, limiting targeted therapy options.
6. What are the latest treatment advances in the U.S.?
Promising options include antibody-drug conjugates like sacituzumab govitecan (Trodelvy) and trastuzumab deruxtecan (T-DXd), and immunotherapies such as pembrolizumab (Keytruda).
7. What advantages does U.S. treatment offer?
Access to advanced therapies, specialized rare cancer programs, experienced multidisciplinary teams, high medical standards, and ongoing clinical trials.
8. What challenges do international patients face?
High costs, limited local treatment options, language barriers, and the need for long-term or repeated stays in the U.S.
9. How can international patients access U.S. experts without traveling?
Through remote video consultations and second opinions via services like Medebound HEALTH, which also offers translation and care coordination.
10. What does treatment in the U.S. cost?
Costs vary by stage and treatment plan. Average one-year breast cancer treatment ranges from about $60,000 for early stage to over $130,000 for stage IV; rare cancer treatments may cost more.
11. Which hospitals in the U.S. are leaders in treating metaplastic breast cancer?
MD Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center.
12. How does Medebound HEALTH help patients?
They arrange expert consultations, create personalized treatment plans, assist with travel, provide translation, negotiate hospital discounts, and offer ongoing recovery support.
Medebound HEALTH: Connecting You to the World's Top Medical Resources
If you or your family members are seeking world-class treatment for complex conditions, Medebound HEALTH is your best choice. Through our partnerships with top-tier medical institutions in the United States, whether through remote video consultations or traveling to the US for treatment, we provide full support every step of the way.
About Medebound HEALTH: Since 2016, we've helped thousands of affluent families mostly from Asia get personalized cancer remote second opinions from the top 1% of US hospitals through simple written opinion or video calls. These are the same top doctors trained or active at top hospitals such as MD Anderson, Mayo Clinic, Memorial Sloan Kettering and Johns Hopkins, etc, you will get their expertise, their treatment suggestion, and their guidance - all from your home. No matter where you live, world-class cancer care is just a few steps away.
Contact Us to Get Started
Email: support@medeboundhealth.com
Website: www.medeboundhealth.com
US Free-toll number: +1 917 342 2381
Submit the form: Click HERE we will get back within 4 hours Instant Chat: Click the chat button at the lower right corner of this page👇
Submit your case today and connect with U.S. experts through Medebound HEALTH.
Disclaimer:
We strive to maintain the accuracy and provide regular updates for the treatment information described in this article. However, treatment outcomes may vary between individuals. The information provided here is not intended as a diagnostic or treatment recommendation and should not replace the careful evaluation and advice of your attending physician
